VEGF-A — Drug Target
All drugs that target VEGF-A — marketed and clinical-stage. Includes 15 drug classes acting on this target.
Drug classes
Anti-VEGF · VEGF-A inhibitor (monoclonal antibody fragment) · VEGF inhibitor (monoclonal antibody fragment) · VEGF inhibitor (monoclonal antibody fragment) combined with laser photocoagulation · Anti-VEGF aptamer · VEGF inhibitor · Anti-VEGF monoclonal antibody fragment · Angiogenesis inhibitor · anti-VEGF agent · Anti-VEGF agent · Angiogenesis inhibitor, Corticosteroid · VEGF inhibitor (monoclonal antibody fragment) combined with thermal ablation guidance
Marketed (6)
- Anti-VEGF drug · Xiaodong Sun · Anti-VEGF · Metabolic
- Lucentis every 4 weeks · Retinal Consultants of Arizona · VEGF-A inhibitor (monoclonal antibody fragment) · Ophthalmology
Lucentis (ranibizumab) blocks vascular endothelial growth factor A (VEGF-A) to inhibit abnormal blood vessel growth and reduce fluid leakage in the retina. - Lucentis every 12 weeks · Retinal Consultants of Arizona · VEGF-A inhibitor (monoclonal antibody fragment) · Ophthalmology
Lucentis (ranibizumab) blocks vascular endothelial growth factor A (VEGF-A) to inhibit abnormal blood vessel growth and reduce fluid leakage in the retina. - Lucentis (Treat and extend) · Retinal Consultants of Arizona · VEGF inhibitor (monoclonal antibody fragment) · Ophthalmology
Lucentis (ranibizumab) blocks vascular endothelial growth factor (VEGF) to reduce abnormal blood vessel growth and leakage in the retina. - Ranibizumab and laser · Fukushima Medical University · VEGF inhibitor (monoclonal antibody fragment) combined with laser photocoagulation · Ophthalmology
Ranibizumab blocks vascular endothelial growth factor (VEGF) to reduce abnormal blood vessel growth and leakage in the retina, while laser photocoagulation thermally destroys abnormal retinal tissue. - Syfovre™ · Hoffmann-La Roche · Anti-VEGF aptamer · Ophthalmology
Syfovre is an anti-VEGF aptamer that binds and inhibits vascular endothelial growth factor (VEGF), reducing abnormal blood vessel growth and leakage in the retina.
Phase 3 pipeline (15)
- Placebo to bevacizumab · Hoffmann-La Roche · VEGF inhibitor · Oncology
Bevacizumab is a recombinant humanized monoclonal antibody that targets vascular endothelial growth factor A (VEGF-A), preventing its interaction with its receptor and thereby inhibiting angiogenesis. - Ranibizumab Control · AbbVie · VEGF-A inhibitor (monoclonal antibody fragment) · Ophthalmology
Ranibizumab is a monoclonal antibody fragment that binds and inhibits vascular endothelial growth factor A (VEGF-A), reducing abnormal blood vessel growth and vascular permeability in the eye. - Brolucizumab Injection [Beovu] · Yeungnam University College of Medicine · Anti-VEGF monoclonal antibody fragment · Ophthalmology
Brolucizumab is a single-chain antibody fragment that inhibits vascular endothelial growth factor A (VEGF-A) to reduce abnormal blood vessel growth and leakage in the retina. - bevacizumab plus chemotherapy · Liaoning Cancer Hospital & Institute · Angiogenesis inhibitor · Oncology
Bevacizumab is a monoclonal antibody that inhibits angiogenesis by binding to vascular endothelial growth factor A (VEGF-A), thereby preventing tumor growth and metastasis. - ranibizumab intravitreal injection · Hawaii Pacific Health · anti-VEGF agent · Ophthalmology
Ranibizumab works by binding to vascular endothelial growth factor A (VEGF-A), preventing its interaction with its receptor and thereby inhibiting angiogenesis. - Ranibizumab + laser · Jaeb Center for Health Research · VEGF inhibitor (monoclonal antibody fragment) · Ophthalmology
Ranibizumab blocks vascular endothelial growth factor (VEGF) to reduce abnormal blood vessel growth, combined with laser photocoagulation to seal leaking vessels in the retina. - rhuFab V2 (ranibizumab) · Genentech, Inc. · VEGF inhibitor · Ophthalmology
Ranibizumab is a recombinant humanized monoclonal antibody fragment that inhibits vascular endothelial growth factor A (VEGF-A). - Ranibizumab + deferred laser · Jaeb Center for Health Research · anti-VEGF agent · Ophthalmology
Ranibizumab is a recombinant humanized monoclonal antibody fragment that inhibits vascular endothelial growth factor A (VEGF-A) by binding to its receptor. - Sham to ranibizumab · Novartis · anti-VEGF agent · Ophthalmology
Ranibizumab is a monoclonal antibody that inhibits vascular endothelial growth factor A (VEGF-A), preventing angiogenesis. - Lucentis intravitreal injection · Medical University of Vienna · VEGF-A inhibitor (monoclonal antibody fragment) · Ophthalmology
Lucentis (ranibizumab) blocks vascular endothelial growth factor A (VEGF-A) to inhibit abnormal blood vessel growth and reduce vascular permeability in the eye. - intravitreal ranibizumab & photodynamic therapy · University Hospital, Basel, Switzerland · Anti-VEGF agent · Ophthalmology
Intravitreal ranibizumab inhibits vascular endothelial growth factor A (VEGF-A) by binding to its receptor, reducing angiogenesis and edema in the retina. - bevacizumab + triamcinolone acetonide · Shahid Beheshti University of Medical Sciences · Angiogenesis inhibitor, Corticosteroid · Oncology
Bevacizumab is a monoclonal antibody that inhibits vascular endothelial growth factor A (VEGF-A), while triamcinolone acetonide is a corticosteroid that reduces inflammation. - Ranibizumab injection and TTT - ICG based · New England Retina Associates · VEGF inhibitor (monoclonal antibody fragment) combined with thermal ablation guidance · Ophthalmology
Ranibizumab is a monoclonal antibody fragment that blocks vascular endothelial growth factor (VEGF) to reduce abnormal blood vessel growth in the retina, combined with transpupillary thermotherapy (TTT) using indocyanine green (ICG) guidance for targeted thermal ablation. - miFL + bevacizumab · Pfizer · VEGF inhibitor · Oncology
miFL is a monoclonal antibody that targets bevacizumab, a vascular endothelial growth factor A (VEGF-A) inhibitor. - Trifluridine/tipiracil + bevacizumab · Second Affiliated Hospital, School of Medicine, Zhejiang University · Antineoplastic · Oncology
Trifluridine/tipiracil is a thymidine kinase 1 inhibitor and tipiracil is a thymidine phosphorylase inhibitor, which work together to inhibit DNA synthesis in cancer cells. Bevacizumab is a monoclonal antibody that targets vascular endothelial growth factor A (VEGF-A), inhibiting angiogenesis.
Phase 2 pipeline (6)
- Bevacizumab maintenance therapy · Sanofi · Angiogenesis inhibitor · Oncology
Inhibits vascular endothelial growth factor A (VEGF-A) - ADVM-022 · Adverum Biotechnologies, Inc. · AAV vector-based gene therapy · Ophthalmology
ADVM-022 is an adeno-associated virus (AAV) vector-based gene therapy that targets the vascular endothelial growth factor A (VEGF-A) gene. - Bevacizumab and FOLFIRI · Gruppo Italiano per lo studio dei Carcinomi dell'Apparato Digerente · VEGF inhibitor, chemotherapy · Oncology
Bevacizumab is a monoclonal antibody that inhibits angiogenesis by binding to vascular endothelial growth factor A (VEGF-A), while FOLFIRI is a chemotherapy regimen that includes irinotecan, a topoisomerase I inhibitor. - Cohort C: bevacizumab · PPD Development, LP · Angiogenesis inhibitor · Oncology
Bevacizumab is a monoclonal antibody that inhibits angiogenesis by binding to vascular endothelial growth factor A (VEGF-A). - Bevacizumab-containing regimen · Hoffmann-La Roche · Angiogenesis inhibitor · Oncology
Bevacizumab-containing regimens work by inhibiting angiogenesis through the blockade of vascular endothelial growth factor A (VEGF-A). - Chemotherapy - Bevacizumab · ARCAGY/ GINECO GROUP · Angiogenesis inhibitor · Oncology
Inhibits vascular endothelial growth factor A (VEGF-A)